The EC’s decision was underpinned by a data set and evidence totality, which included findings from a Phase III trial.

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion, a major Korean biopharmaceutical firm, said Monday its new biosimilar for an autoimmune disease treatment has ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...